Press Releases

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, Feb. 11, 2014. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review fourth quarter and full year 2013 financial results, discuss 2014 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Feb. 11, 2014. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both ...

The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a first quarter dividend payable to holders of the company’s common stock of $0.072 per share, an increase of 11% from the quarterly dividend rate paid in 2013. The dividend is to be paid on Mar. 4, 2014, to holders of record on Jan. 30, 2014. “Since our IPO in February, we have been able to demonstrate the strength of our business model as an independent company and our commitment to generating long-term value for shareholders,” said Zoetis Chief Executive Officer Juan Ramón Alaix. “With the Board’s approval, we are increasing our dividend as we head into 2014 and continuing our commitment to effective and efficient use of our cash.” About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, ...

Zoetis Inc. (NYSE:ZTS) will participate in the 2013 Bank of America Merrill Lynch Animal Health Summit on Monday, December 16, at the Bank of America Conference Center in Boston, MA. Juan Ramón Alaix, chief executive officer of Zoetis, will represent the company as the keynote speaker and respond to questions from analysts. He is scheduled to present at 12:35 pm. Investors and other interested parties will be able to access the presentation materials by visiting http://investor.zoetis.com/events-presentations after the keynote speech is delivered. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 ...

Zoetis Inc. (NYSE:ZTS) will participate in the 25 th Annual Piper Jaffray Healthcare Conference on Tuesday, Dec. 3, at the New York Palace Hotel in New York City. Rick Passov, executive vice president and chief financial officer of Zoetis, will represent the company as a speaker and respond to questions from analysts. He is scheduled to present at 11:30 a.m. (ET) Investors and other interested parties may register and access the live webcast by visiting the Conference website, http://www.media-server.com/m/p/zu6pbsco, at 11:30 a.m. (ET). on Dec. 3, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 ...

Third Quarter 2013 Revenue of $1.1 Billion Increased 8% Compared to Third Quarter 2012 Third Quarter 2013 Reported Net Income of $131 Million, or Diluted EPS of $0.26, Decreased 19%, Compared to Third Quarter 2012 Third Quarter 2013 Adjusted Net Income of $172 Million, or Adjusted Diluted EPS 1 of $0.34, Increased 12% and 10%, Respectively, Compared to Third Quarter 2012 Narrows Full-Year 2013 Adjusted Diluted EPS 1 Guidance to $1.38 - $1.42 Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2013. The company reported revenue of $1.1 billion for the third quarter of 2013, an increase of 8% from the third quarter of 2012. Revenue reflected an operational 2 increase of 9%, with foreign currency having a negative impact of 1 percentage point. Net income for the third quarter of 2013 was $131 million, or $0.26 per diluted share, a decrease of 19%, compared to the third quarter of 2012. Adjusted net income1 for the third quarter of 2013 was $172 million, ...

Zoetis Inc. (NYSE:ZTS) today announced that it has extended until Oct. 30, 2013 at 5:00 p.m., New York City time, the expiration date of its offer to exchange: $400,000,000 aggregate principal amount of its unregistered 1.150% Senior Notes due 2016 (the “2016 unregistered notes”) for a like principal amount of its 1.150% Senior Notes due 2016 that have been registered under the Securities Act of 1933; $750,000,000 aggregate principal amount of its unregistered 1.875% Senior Notes due 2018 (the “2018 unregistered notes”) for a like principal amount of its 1.875% Senior Notes due 2018 that have been registered under the Securities Act of 1933; $1,350,000,000 aggregate principal amount of its unregistered 3.250% Senior Notes due 2023 (the “2023 unregistered notes”) for a like principal amount of its 3.250% Senior Notes due 2023 that have been registered under the Securities Act of 1933; and $1,150,000,000 aggregate principal amount of its unregistered 4.700% Senior Notes due 2043 (the ...

Zoetis Inc. (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, Nov. 5, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review third-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Nov. 5, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary ...

The Board of Directors of Zoetis Inc. (NYSE:ZTS), formerly the animal health business of Pfizer Inc., has declared a fourth-quarter dividend payable to holders of the company’s common stock of $0.065 per share. The dividend is to be paid on Dec. 2, 2013, to holders of record on Nov. 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2012, the company generated annual revenues of $4.3 billion. With approximately 9,300 employees worldwide at the beginning of 2013, Zoetis has a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise ...

Zoetis Inc. (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, Aug. 6, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review second-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on Aug. 6, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines ...

Zoetis Inc. (NYSE: ZTS) announced it intends to file a Registration Statement on Form S-4 with the Securities and Exchange Commission (SEC) today in connection with the proposed exchange offer announced by Pfizer Inc. (NYSE: PFE). As part of the offer, Pfizer shareholders will be able to exchange all, some or none of their shares of Pfizer common stock for shares of Zoetis common stock. Pfizer currently holds approximately 80% of the outstanding common stock of Zoetis. If the exchange offer is fully subscribed, Pfizer will no longer have a controlling ownership interest in Zoetis, and Zoetis will become a fully independent company upon completion of the exchange offer. If the exchange offer is undersubscribed, Pfizer would distribute less than 400,985,000 shares of Zoetis common stock. In that case, Pfizer would continue to own an interest in Zoetis and, depending on the number of shares of Zoetis common stock distributed in the exchange offer, Pfizer could retain voting control of ...

First-Quarter 2013 Revenues of $1.09 Billion Increased 4% Compared to First Quarter 2012 First-Quarter 2013 Reported Net Income of $140 Million, or Diluted EPS of $0.28, Increased 26% and 27%, respectively, Compared to First Quarter 2012 First-Quarter 2013 Adjusted Net Income 1 of $179 Million, or Adjusted Diluted EPS 1 of $0.36, Increased 18% and 20%, respectively, Compared to First Quarter 2012 Company Provides Full-Year 2013 Adjusted Diluted EPS 1 Guidance of $1.36 - $1.42 Zoetis TM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., today reported its financial results for the first quarter of 2013. The company reported revenues of $1.09 billion for the first quarter, an increase of 4% from the first quarter of 2012. Revenues reflected an operational 2 increase of 5%, with foreign currency having a negative impact of 1%. Net income for the first quarter of 2013 was $140 million, or $0.28 per diluted share, an increase of 26% and 27%, respectively, compared to the ...

The Board of Directors of Zoetis TM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., has declared a second-quarter dividend payable to holders of the company’s Class A common stock and Class B common stock of $0.065 per share. The dividend is to be paid on June 6, 2013, to holders of record on May 1, 2013. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. The company generated annual revenues of $4.3 billion in 2012. It has more than 9,300 employees worldwide and a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 ...

Zoetis TM (NYSE: ZTS), formerly the animal health business of Pfizer Inc., will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, April 30, 2013. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Rick Passov will review first-quarter 2013 financial results, discuss 2013 financial guidance, and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://www.zoetis.com/events-and-presentations. Information on accessing and pre-registering for the webcast is available beginning today. A replay of the webcast will be archived and made available on April 30. About Zoetis Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and ...

Zoetis TM (NYSE:ZTS), formerly the animal health business unit of Pfizer Inc., today announced the closing of its previously announced initial public offering. The offering of 99,015,000 shares of its Class A common stock included 12,915,000 shares of Class A common stock that were sold pursuant to the underwriters’ option to purchase additional shares, which was exercised in full prior to the closing. Zoetis did not receive any of the proceeds of the offering. Following the completion of the initial public offering, Pfizer owns 100% of the outstanding Class B common stock of Zoetis and retains an approximately 80% ownership of Zoetis. J.P. Morgan, BofA Merrill Lynch and Morgan Stanley served as joint lead book-running managers for the offering. Barclays, Citigroup, Credit Suisse, Deutsche Bank Securities, Goldman, Sachs & Co., Guggenheim Securities and Jefferies served as book-running managers for the offering. BNP PARIBAS, HSBC, Loop Capital Markets, RBC Capital Markets, The ...

MADISON, N.J.-ZoetisTM, formerly the animal health business unit of Pfizer Inc., today announced the pricing of its initial public offering of 86,100,000 shares of its Class A common stock at $26 per share. The shares are expected to begin trading tomorrow, Feb. 1, on the New York Stock Exchange under the symbol “ZTS.” Zoetis will not receive any of the proceeds of the offering. Following the completion of the initial public offering, Pfizer will own 100% of the outstanding Class B common stock of Zoetis and will retain an approximately 83 percent ownership of Zoetis. The underwriters also have an option to purchase up to an additional 12,915,000 shares of Class A common stock. Zoetis will not receive any of the proceeds from any shares sold pursuant to this option. If the underwriters exercise this option in full, Pfizer is expected to retain an approximately 80 percent ownership of Zoetis. J.P. Morgan, BofA Merrill Lynch and Morgan Stanley served as joint lead book-running managers ...